Optimizing Care in Lung Cancer: Current and Emerging Biomarkers for Immuno-Oncology

Join us for an exciting live webinar held during ASTRO’s 62nd Annual Meeting. Experts, Jamie E. Chaft, MD and  Kristin Higgins, MD discuss interdisciplinary approaches for optimizing the use of immune checkpoint inhibitor therapy for treating patients with lung cancer with a focus on how IO biomarkers can help guide treatment decisions and how radiotherapy interfaces with IO-based treatment approaches.

The American Society for Radiation Oncology (ASTRO) has reviewed and approved this symposium as appropriate for presentation as an Industry Satellite Symposium. The symposium constitutes the content and views of the provider and is not part of the official ASTRO Annual Meeting program.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

Welcome and Introduction

Immunotherapy in Lung Cancer: The Role of IO Biomarkers in Treatment Choice
Patient Case Discussions Highlighting

  • Current ICI single agent and combination indications in lung cancer
  • In which setting is PD-L1 testing most clearly indicated for shaping clinical decisions?
  • When PD-L1 expression guides ICI therapy choices and when it does not
  • Radiation therapy considerations and rationale for its combined use with immunotherapy in each stage of disease

Immunotherapy for Early Stage NSCLC: On the Horizon

Working Effectively with the Clinical Care Team Through Shared Knowledge: Specialty Viewpoints

Final Thoughts and Audience Q&A

 

 

Faculty

Program Director
Jamie Chaft, MD

Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty
Kristin Higgins, MD

Medical Director
Associate Professor

Department of Radiation Oncology
Emory University
Atlanta, Georgia

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to provide optimal care for their patients with lung cancer.

Target Audience
This program is intended for radiologists, medical oncologists, and other healthcare providers who care for patients with lung cancer.

Learning Objectives
At the conclusion of this activity, learners should be able to:

  • Apply new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Consider patients for enrollment in clinical trials investigating novel therapeutic approaches, including neoadjuvant/adjuvant immunotherapy in lung cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.